Loading cancer entity…
Loading cancer entity…
Clinical trials
972 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (145)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04486391 | Tislelizumab Monotherapy Versus Salvage Chemotherapy for Relapsed/Refractory Classical Hodgkin Lymphoma | terminated | Phase 3 | 3 | BeiGeneINDUSTRY | 1 | Mar 2, 2026 | clinicaltrials |
| NCT05181540 | A Study of the Effects of AB-205 in Patients With Lymphoma Undergoing Autologous Hematopoietic Cell Transplantation(E-CELERATE) | terminated | Phase 3 | 130 | Angiocrine BioscienceINDUSTRY | 1 | Feb 4, 2025 | clinicaltrials |
| NCT03138499 | A Study of Nivolumab Plus Brentuximab Vedotin Versus Brentuximab Vedotin Alone in Patients With Advanced Stage Classical Hodgkin Lymphoma, Who Are Relapsed/ Refractory or Who Are Not Eligible for Autologous Stem Cell Transplant,(CheckMate 812) | terminated | Phase 3 | 23 | Bristol-Myers SquibbINDUSTRY | 3 | Jan 10, 2024 | clinicaltrials |
| NCT00992030 | R-ABVD vs ABVD-RT in Early Stage Hodgkin's Lymphoma | terminated | Phase 3 | 112 | Fondazione MichelangeloOTHER | 2 | Aug 19, 2021 | clinicaltrials |
Data updated 22 days agoSource updated Mar 2, 2026source: clinicaltrials